PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29513760-6	2018	Several inflammatory molecules upregulated by tumor necrosis factor-alpha in human retinal vascular endothelial cells were markedly reduced by metformin, including nuclear factor kappa B p65 (NFkappaB p65), intercellular adhesion molecule-1 (ICAM-1), monocyte chemotactic protein-1 (MCP-1), and interleukin-8 (IL-8).	Metformin	143-152	C-C motif chemokine ligand 2	Homo sapiens	251-281	
32967076-5	2020	Patients treated with metformin showed decreased levels of all analyzed serum pro-inflammatory markers (TNFalpha, IL6, IL1beta and MCP1) and a downwards trend in IL18 levels associated with a lower production of oxidative stress markers in leukocytes (mitochondrial ROS and myeloperoxidase (MPO)).	Metformin	22-31	C-C motif chemokine ligand 2	Homo sapiens	131-135	
31840936-12	2020	Metformin or AICAR presence decreased spontaneous production of IL-6, IL-8 and MCP-1 in RA synovial explants and SFCs (n=5-7).	Metformin	0-9	C-C motif chemokine ligand 2	Homo sapiens	79-84	
31851935-3	2019	Metformin interrupts bidirectional signaling between tumor and mesothelial cells by blocking OvCa cell TGF-beta signaling and mesothelial cell production of CCL2 and IL-8.	Metformin	0-9	C-C motif chemokine ligand 2	Homo sapiens	157-161	
32911202-0	2020	Effect of metformin and insulin combination on monocyte chemoattractant protein-1 and cathepsin-D in type 2 diabetes mellitus.	Metformin	10-19	C-C motif chemokine ligand 2	Homo sapiens	47-81	
32911202-7	2020	CONCLUSION: Patients treated with metformin and insulin combination had lower serum MCP-1 and cathepsin-D levels which suggests that this combination may be more effective in reducing the progression of diabetic retinopathy.	Metformin	34-43	C-C motif chemokine ligand 2	Homo sapiens	84-89	
31753516-11	2020	More importantly, metformin inhibited LPS-enhanced CCL-2 synthesis through modulation of the iNOS/NO pathway.	Metformin	18-27	C-C motif chemokine ligand 2	Homo sapiens	51-56	
29630425-8	2018	RESULTS: Metformin suppressed LPS-induced IP-10 and MCP-1 production as well as LPS-induced phosphorylation of c-Jun N-terminal kinase (JNK), p38, extracellular signal-regulated kinase (ERK), and nuclear factor-kappa B (NF-kappaB).	Metformin	9-18	C-C motif chemokine ligand 2	Homo sapiens	52-57	
29513760-6	2018	Several inflammatory molecules upregulated by tumor necrosis factor-alpha in human retinal vascular endothelial cells were markedly reduced by metformin, including nuclear factor kappa B p65 (NFkappaB p65), intercellular adhesion molecule-1 (ICAM-1), monocyte chemotactic protein-1 (MCP-1), and interleukin-8 (IL-8).	Metformin	143-152	C-C motif chemokine ligand 2	Homo sapiens	283-288	
29513760-8	2018	Activation of AMP-activated protein kinase was found to play a partial role in the suppression of ICAM-1 and MCP-1 by metformin, but not in those of NFkappaB p65 and IL-8.	Metformin	118-127	C-C motif chemokine ligand 2	Homo sapiens	109-114	
27904436-6	2016	RESULTS: We found that metformin reduced the levels of IL-6 in blood and MCP-1 in urine, but increased IL-10 levels in blood of patients with type 2 diabetes.	Metformin	23-32	C-C motif chemokine ligand 2	Homo sapiens	73-78	
27904436-8	2016	Furthermore, compared to individual drug treatment, metformin significantly reduced the levels of serum IL-6 and TNF-alpha, as well as urine MCP-1.	Metformin	52-61	C-C motif chemokine ligand 2	Homo sapiens	141-146	
27904436-10	2016	Metformin (1.5 g) treatment reduced the urinary levels of MCP-1 as compared with dose of 1.0 g in patients with type 2 diabetes.	Metformin	0-9	C-C motif chemokine ligand 2	Homo sapiens	58-63	
26294325-5	2015	Of the top 10 genes (fold-change > 10, P < 10(-10)) regulated by metformin plus aspirin, PCDH18, CCL2, RASL11A, FAM111B and BMP5 were down-regulated >= 20-fold, while NGFR, NPTX1, C7orf57, MRPL23AS1 and UNC5B were up-regulated >= 10-fold.	Metformin	71-80	C-C motif chemokine ligand 2	Homo sapiens	103-107	
26963617-12	2016	In the SHR-CRP transgenic strain, we found that metformin treatment decreased circulating levels of inflammatory response marker IL-6, TNFalpha and MCP-1 while levels of human CRP remained unchanged.	Metformin	48-57	C-C motif chemokine ligand 2	Homo sapiens	148-153	
27633039-0	2016	Relationships Between Metformin, Paraoxonase-1 and the Chemokine (C-C Motif) Ligand 2.	Metformin	22-31	C-C motif chemokine ligand 2	Homo sapiens	55-85	
26467463-9	2015	RESULTS: Metformin induced single-cultured RAW264.7 macrophages with an M2 phenotype but attenuated the M2 macrophage differentiation and inhibited monocyte chemoattractant protein-1 (MCP-1) secretion in a co-culture system.	Metformin	9-18	C-C motif chemokine ligand 2	Homo sapiens	148-182	
26467463-9	2015	RESULTS: Metformin induced single-cultured RAW264.7 macrophages with an M2 phenotype but attenuated the M2 macrophage differentiation and inhibited monocyte chemoattractant protein-1 (MCP-1) secretion in a co-culture system.	Metformin	9-18	C-C motif chemokine ligand 2	Homo sapiens	184-189	
27424158-13	2016	Exenatide was more effective than metformin in reducing MCP-1 expression and JNK activity.	Metformin	34-43	C-C motif chemokine ligand 2	Homo sapiens	56-61	
24399727-6	2013	RESULTS: Metformin treatment reduced plasma C-reactive protein levels and monocyte release of tumor necrosis factor-alpha and interleukin-6, as well as tended to reduce monocyte release of interleukin-1beta and monocyte chemoattractant protein-1, which was accompanied by an improvement in insulin sensitivity.	Metformin	9-18	C-C motif chemokine ligand 2	Homo sapiens	211-245	
23431246-7	2013	HE3286 HbA1c decrease correlated with weight loss and inversely with baseline monocyte chemoattractant protein-1 (MCP-1) in metformin-treated diabetics.	Metformin	124-133	C-C motif chemokine ligand 2	Homo sapiens	78-112	
23431246-7	2013	HE3286 HbA1c decrease correlated with weight loss and inversely with baseline monocyte chemoattractant protein-1 (MCP-1) in metformin-treated diabetics.	Metformin	124-133	C-C motif chemokine ligand 2	Homo sapiens	114-119	
26120598-6	2015	Further investigation into the effects of metformin suggest that the drug directly activates AMPK and dose-dependently suppressed the release of TNF-alpha, IL-6, and MCP-1 by macrophages while enhancing the release of IL-10 in vitro.	Metformin	42-51	C-C motif chemokine ligand 2	Homo sapiens	166-171	
22841520-5	2013	RESULTS: Compared to placebo, metformin reduced monocyte release of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, monocyte chemoattractant protein-1 and interleukin-8, as well as decreased plasma C-reactive protein levels, which were accompanied by an improvement in insulin sensitivity.	Metformin	30-39	C-C motif chemokine ligand 2	Homo sapiens	131-165	
22100460-6	2012	Compared with AGEs-modified BSA prepared without metformin (AGEs-MF0), those prepared in the presence of 30 mM or 100 mM metformin (AGEs-MF30 or AGEs-MF100) significantly reduced RAGE mRNA level, reactive oxygen species (ROS) generation, apoptosis, monocyte chemoattractant protein-1 and transforming growth factor-beta mRNA level in tubular cells.	Metformin	121-130	C-C motif chemokine ligand 2	Homo sapiens	249-319	
19674806-7	2009	Serum MMP-9 levels were decreased in the metformin (-13.5+/-34.8%, p=0.02) and rosiglitazone (-27.2+/-51.0%, p=0.023) groups compared with baseline values, whereas no significant change was seen in serum MCP-1 levels.	Metformin	41-50	C-C motif chemokine ligand 2	Homo sapiens	204-209	
15671098-6	2005	MCP-1 is stimulated by IL-1beta, TNF-alpha, IL-8, IL-4, and IL-6 + IL-6-soluble receptor and is decreased by dexamethasone, IL-10, metformin, and thiazolidinediones.	Metformin	131-140	C-C motif chemokine ligand 2	Homo sapiens	0-5	
15671098-8	2005	Despite this, MCP-1 may be involved in obesity-related health complications, and the decrease of MCP-1 by metformin and thiazolidinediones suggests that these antidiabetic compounds have antiinflammatory properties improving the low-grade inflammatory state observed in obesity.	Metformin	106-115	C-C motif chemokine ligand 2	Homo sapiens	97-102	
20956498-10	2011	Furthermore, metformin decreased IL-6 and MCP-1 gene expression in comparison with differentiated adipocytes.	Metformin	13-22	C-C motif chemokine ligand 2	Homo sapiens	42-47	
16636195-6	2006	Furthermore, metformin attenuated the TNF-alpha-induced gene expression of various proinflammatory and cell adhesion molecules, such as vascular cell adhesion molecule-1, E-selectin, intercellular adhesion molecule-1, and monocyte chemoattractant protein-1, in HUVECs.	Metformin	13-22	C-C motif chemokine ligand 2	Homo sapiens	222-256